NCT03913936 is a NA clinical trial of YES portal in Breast Cancer, sponsored by Dana-Farber Cancer Institute.

Who is sponsoring NCT03913936?

NCT03913936 is sponsored by Dana-Farber Cancer Institute.

What drugs are being tested in NCT03913936?

Interventions in NCT03913936: YES portal.

What condition does NCT03913936 study?

NCT03913936 studies Breast Cancer.

Is NCT03913936 still recruiting?

NCT03913936 is currently completed. Last updated 24 April 2025.

Last reviewed 2025-04-24 · How we verify

NCT03913936

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

Completed NA Last updated 24 April 2025

What this trial tests

NA trial testing YES portal in Breast Cancer in 30 participants. Completed in 19 September 2019.

Timeline

23 May 2019

Primary endpoint
19 September 2019

19 September 2019

Quick facts

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	30
Start date	23 May 2019
Primary completion	19 September 2019
Estimated completion	19 September 2019
Sites	1 location across United States

Drugs / interventions tested

YES portal

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Dana-Farber Cancer Institute

Who can join

Adults 18 to 44, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study is piloting a new internet-based research tool (YES portal). The main purpose of this pilot study is to test the web-based interface.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Young, Empowered & strong (YES): a study protocol paper for a randomized controlled trial of an mHealth symptom monitoring and self-management intervention for adolescent and young adult (AYA) breast cancer survivors.
Dibble KE, Rosenberg SM, Snow C, Kirkner GJ, et al · · 2025 · cited 1× · PMID 39799291 · DOI 10.1186/s12889-025-21288-4

Verify or expand the search:

Other trials of YES portal

Trials testing the same drug.

NCT04379414 — YES Study - Newly Diagnosed/Metastatic Intervention · NA · active not recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Dana-Farber Cancer Institute trials

Trials by the same sponsor.

NCT07519200 — Sexual Health and Rehabilitation for Women With Metastatic Breast Cancer (SHARE-MC): An Educational Intervention · NA · not yet recruiting
NCT07499999 — Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk fo · Phase 2 · not yet recruiting
NCT05825469 — Development and Testing of Nutritional Algorithms (NACHO) · NA · not yet recruiting
NCT07516353 — my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults · NA · not yet recruiting
NCT07513324 — Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03913936 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dana-Farber Cancer Institute
Last refreshed: 24 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913936.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing